American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S3-S9 , September 2007

Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions

  • Mary Glenn Fowler, MD, MPH

      Affiliations

    • Department of Pathology, Johns Hopkins Medical School, onsite Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
    • Corresponding Author InformationReprints: Mary Glenn Fowler, MD, MPH, Onsite Johns Hopkins Investigator, MU-JHU Research Collaboration, Upper Mulago Hill Road, Kampala, Uganda
    • ,
  • Margaret A. Lampe, RN, MPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
    • ,
  • Denise J. Jamieson, MD, MPH

      Affiliations

    • Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
    • ,
  • Athena P. Kourtis, MD, PhD, MPH

      Affiliations

    • Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
    • ,
  • Martha F. Rogers, MD

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 21 June 2007 ,Accepted 26 June 2007.

References 

  1. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA. 2002;288:189–198
  2. Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1985;34:721–732
  3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment (Pediatric AIDS Clinical Trials Group Protocol 076 Study Group). N Engl J Med. 1994;331:1173–1180
  4. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1994;43(No. RR-11):1–21
  5. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep. 1995;44:7
  6. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retroviral. 2002;29:484–494
  7. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet. 1999;353:1035–1039
  8. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977–987
  9. American College of Obstetricians and Gynecologists. Committee opinion: scheduled cesarean delivery and the prevention of vertical transmission of HIV infection (No. 234). Washington, DC: American College of Obstetricians and Gynecologists; 2000;
  10. Bulterys M, Jamieson DJ, O’Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multi-center study. JAMA. 2004;292:219–223
  11. Gerberding JL, Jaffe HW. Dear colleague letter. Atlanta, GA: US Department of Health and Human Services, CDC; 2003;April 22, Available at: http://www.cdc.gov/hiv/topics/perinatal/resources/other/dear_colleague-2003.htm. Accessed March 11, 2007.
  12. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep. 2006;55(no. RR-14):1–16
  13. American College of Obstetricians and Gynecologists. Technical bulletin 232. Human immunodeficiency virus infections. Washington, DC: American College of Obstetricians and Gynecologists; 1997;
  14. Institute of MedicineNational Research Council. Reducing the odds: preventing perinatal transmission of HIV in the United States. Washington (DC): National Academy Press; 1999;
  15. American College of Obstetricians and Gynecologists. Human immunodeficiency virus screening (Joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists). Pediatrics. 1999;104:128
  16. ACOG Committee opinion number 304, November 2004 (Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations). Obstet Gynecol. 2004;104:1119–1124
  17. Centers for Disease Control and Prevention. Rapid HIV-1 antibody testing during labor and delivery for women of unknown HIV status: a practical guide and model protocol. 2004;January, Available at: cdc.gov/hiv/projects/perinatal/guidelines.htm. Accessed March 11, 2007.
  18. Shaffer N, Chuachoowong R, Mock PA, et al. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized trial. Lancet. 1999;353:773–780
  19. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire. Lancet. 1999;353:781–785
  20. Dabis F, Msellati P, Meda N, et al. Six month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double blind placebo controlled multicentre trial. Lancet. 1999;353:786–792
  21. The PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomized double-blind placebo-controlled trial. Lancet. 2002;359:1178–1186
  22. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802
  23. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HVNET 012 randomised trial. Lancet. 2003;362:859–868
  24. Lallemant M, Jourdain G, LeCouer S, et al. Single dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–228
  25. Dabis F, Leroy V, Bequet L, et al. Effectiveness of a short course of zidovudine + nevirapine to prevent mother-to-child transmission (PMTCT) of HIV-1: the Ditrame Plus ANRS 1201 Project in Abidjan, Cote d’Ivoire. In: Presented at the 14th International AIDS Conference, July 7-12, Barcelona, Spain. 2002;(Abstract ThOrD11428)
  26. Duerr A, Hurst S, Kourtis AP, Rutenberg N, Jamieson DJ. Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings. Lancet. 2005;366:261–263
  27. Homsy J, Bunnell R, King R, et al. Determinants of pregnancy among women receiving HAART in rural Uganda. In: Presented at the XVIth International Conference on AIDS, August 12-16, Toronto, Canada. 2006;(Poster WEPE0294, Abstract book vol. 2, p. 103)
  28. Mohohlo M. Pregnancy-related events in an antiretroviral treatment program. In: Presented at the 2006 HIV/AIDS Implementer Meeting of the President’s Emergency Plan for AIDS Relief, June 12-15, Durban, South Africa. 2006;(Abstract 113)
  29. Joint United Nations Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic. Available at: http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH06_en.pdf. Accessed May 22, 2007.
  30. World Health Organization. HIV and infant feeding technical consultation held on behalf of the Inter-agency Task Team on Prevention of HIV Infections in Pregnant Women, Mothers and Their Infants. 2006;Geneva, October 25-27, Available at: http://www.who.int/child-adolescent-health/publications/NUTRITION/consensus_statement.htm. Accessed March 11, 2007.
  31. Kafulafula G, Thigpen M, Hoover D, et al. Post-weaning gastroenteritis and mortality in HIV-uninfected African infants receiving antiretroviral prophylaxis to prevent MTCT of HIV-1. In: Presented at the XIV Conference on Retroviruses and Opportunistic Infections, Feb. 25-27. 2007;Los Angeles, CA (Program and Abstracts, Abstract 773, p. 359)
  32. Thomas T, Masaba R, van Eijk A, et al. Rates of diarrhea associated with early weaning among infants in Kisumu, Kenya. In: Presented at the XIV Conference on Retroviruses and Opportunistic Infections, Feb. 25-27. 2007;Los Angeles, CA (Program and Abstracts, Abstract 774, p. 360)
  33. Oyango C, Mmiro F, Bagenda D, et al. Early breastfeeding cessation among HIV exposed negative infants and risk of serious gastroenteritis: finding from a perinatal prevention trial in Kampala Uganda. In: Presented at the XIV Conference on Retroviruses and Opportunistic Infections, Feb. 25-27. 2007;Los Angeles, CA (Program and Abstracts, Abstract 775, p. 360)
  34. Centers for Disease Control and Prevention. Recommendations to improve preconception health and health care—United States. MMWR Morb Mortal Wkly Rep. 2006;55:1–13

 The views expressed herein are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

PII: S0002-9378(07)00824-1

doi: 10.1016/j.ajog.2007.06.048

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S3-S9 , September 2007

Article Tools